The IMMUNOTARGET registry showed that ICI by itself in EGFR-mutated NSCLC had a shorter median progression-free survival (PFS) of 2.1 months and a lower overall response rate (ORR) of 12% compared to other targetable mutations (18). This evidence concerns the gene EGFR and non-small cell lung carcinoma.